Frequency of loss of heterozygosity of E-cadherin gene in gastric cancer

Yıl 2006, Cilt: 5 Sayı: 3, 149 - 152, 01.12.2006

İsmail Yeğin Ömer Yılmaz Bülent Aydınlı Kerim Çayır Selma Gepdiremen İbrahim Pirim Salim Başol Tekin

Öz

Background/aim: Gastric cancer is the most frequent malignancy in gastrointestinal cancers in our country. E-cadherin is an adhesion molecule which plays a role in many events like the preservation of tissue integrity, tumor invasion and tumor metastasis. The aim of this study was to determine the frequency of loss of heterozygosity (LOH) of E-cadherin gene in gastric cancer in our region. Materials and methods: 25 patients who admitted with the complaints of abdominal pain, nausea and vomiting, hematemesis and weight loss and were diagnosed as gastric cancer were enrolled in this study. Histopathological examination of biopsy specimens confirmed the clinical diagnosis of gastric cancer. DNA isolation was made from the specimens, and LOH in E-cadherin gene was detected by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) technique. Results: Of diffuse type gastric cancer cases (n=3) according to Lauren Classification, LOH was determined in 1 patient (33.3%). No LOH was determined in 22 patients with intestinal type gastric cancer. Thus, LOH frequency was only 4% among all cases. Conclusion: As LOH was determined only in a diffuse type gastric cancer biopsy material, there may be a relation between them.

Anahtar Kelimeler

Gastric cancer, E-cadherin, loss of heterozygosity

Mide kanserinde E-cadherin genindeki heterozigosite kaybının sıklığı

Öz

Giriş ve amaç: Ülkemizde mide kanseri gastrointestinal kanserler içerisinde ilk sırada yer alır. E-cadherin bir adezyon molekülüdür ve doku bütünlüğünün korunması, tümör invazyonu ve tümör metastazı gibi birçok olayda rol alır. Çalışmamızda bölgemizdeki mide kanserlerinde E-cadherin geninde heterozigosite kaybı (LOH) sıklığını araştırdık. Gereç ve yöntem: Karın ağrısı, bulantı-kusma, hematemez ve kilo kaybı şikayetleri nedeniyle müracaat eden ve mide kanseri tanısı konulan 25 hasta dahil edildi. Alınan materyallerin histopatolojik inceleme sonucu kanser olduğu doğrulandı. Örneklerden usulüne uygun olarak DNA izolasyonu yapıldı. Elde edilen DNA örneklerinden PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) tekniği ile E-cadherin genindeki LOH düzeyine bakıldı. Bulgular: Lauren sınıflamasına göre Diffüz tip vakalardan bir tanesinde LOH tespit edildi (%33,3). İntestinal tip vakalardan 22 hastamızda LOH tespit edilemedi. Tespit edilen LOH 25 vaka göz önüne alındığında %4 oranında idi. Sonuç: LOH, sadece diffüz tip mide kanseri materyallerinde tespit edildi. Bundan dolayı diffüz tip mide kanseri gelişimi ile LOH kaybı arasında ilişki olabilir.

Anahtar Kelimeler

Mide kanseri, E-cadherin, heterozigosite kaybı

Kaynakça

• Hamilton JP, Meltzer SJ. A review of the genomics of gastric can- cer. Clin Gastroenterol Hepatol 2006; 4: 416-25.
• Karpeh MS, Kelsen DP, Teper JE: Cancer of the stomach In: DeVi- ta VT, Hellman S, Rosenberg SA eds. Cancer Principles And Prac- tice of Oncology. 6th. Edition, Philadelphia, JB Lippincott Comp, 2001; 1092-126.
• Becker KF, Keller G, Hoefler. The use of molecular biology in diag- nosis and prognosis of gastric cancer. Surgical Oncology 2000; 9: 5-11.
• Truszkowski JA, Summers RW. Colorectal Neoplasms. Postgraduate Medicine 1996; 98: 20-5.
• Sherman CD. Klinik Onkoloji. Türk Kanser Araştırma ve Savaş Ku- rumu Yayınları, Ankara. 1990: 3-9.
• AOO Chan, SK Lam, KM Chu, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001; 48: 808-11.
• Slaus NP. Tumor supressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell International 2003; 3: 1-7.
• Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5.
• Paul S, Frenette MD, Denısa D, et al. Adhesion Molecules-Part I. The new england journal of medicine 1996; 6: 1526-9.
• Brunner EC, Romeike BF, Jung M, et al. Altered expression of be- ta-catenin/E-cadherin in meningiomas. Histopathology 2006; 49: 178-87.
• Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol 2006; 37: 1042-9 .
• Liu YC, Shen CY, Wu HS, et al. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroente- rol 2006; 12: 2168-73.
• Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a his- toclinical classification. Acta Pathol Microbiol Scand 1965; 64: 31.
• Werner M, Becker KF, Keller G, et al. Gasric adenocarcinoma: pat- homorphology and molecular pathology. J Cancer Res Clin Oncol 2001; 127: 207-16.
• Cossman J, Schlgel R. P53 in the Diagnosis of Human Neoplasia. J of the Natl Cancer Inst 1991; 83: 980-1.
• Petty EM, Carstens R, Bale AE. Ornithine transcarbamylase poly- morphism detected by PCR introduction of Dral site. Nucleic Acids Research 1994; 19: 690.
• Robbins SL, Kumar V. Robbins and Kumar Basic Pathology. Uluoğ- lu Ö, Patoloji, Ankara, Güneş Yayınevi 1990. s: 678-83.
• Shimoyama Y, Hirohashi S. Expression of E- and P-cadherin in gastric carcinoma. Cancer res 1991; 51: 2185-92.
• Oka H, Shiozaki H, Kobayashi K, et al. Immunohistochemical eva- luation of E-cadherin adhesion molecule expression in human gast- ric cancer. Virchows Arch A Pathol Anat Histopathol 1992; 421: 149-56.
• Cho JH, Noguchi M, Ochiai A, et al. Loss of heterozigosity of mul- tiple tumor suppressor genes in human gastric cancers by polyme- rase chain reaction. Lab Invest 1996; 74: 835-41.
• Wang D, Fang D, Luo Y, et al. Study of heterozigosity at DCC and APC/MCC genetic loci of gastric cancer. Chin Med Sci J 1999; 14: 107-11.
• Wang Y, Zheng E, Ke Y. Studies of loss of heterozigosity (LOH) in Chinese human gastric cancer tissues. Zhoghua Zhong Liu Za Zhi 1998; 20: 116-8.
• Machado JC, Soares P, Carneiro F, et al. E-cadherin gene mutati- ons provide a genetic basis for the phenotypic divegence of mixed gastric carcinomas. Lab Invest 1999; 79: 459-65.
• Jennifer J, Ascano MS, Henry F, et al. Inactivation of the E-cadhe- rin gene in sporadic diffuse-type gastric cancer. Mod Pathol 2001; 14: 942-9.
• Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001; 20: 1525-8.
• Kimura T, Sato H, Manabe R, et al. Analysis of microsatellite regi- ons and DNA ploidy pattern in signet ring cell carcinomas of the stomach. Gan To Kagaku Ryoho 1997; 24: 273-8.
• Huiping C, Kristjansdottir S, Jonasson JG, et al. Alterations of E- cadherin and β-catenin in gastric cancer. BMC Cancer 2001; 1: 16
• Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 2006; 12: 192-8.
• Schwarz A. Preventive gastrectomy in patients with gastric cancer risk due to genetic alterations of the E-cadherin gene defect. Langenbecks Arch Surg 2003; 388: 27-32.